Valuation dashboard for Atlantic International Corp. (ATLN) with P/E N/A, P/B 7.10, EV/EBITDA -3.31 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Based in Billerica, Massachusetts, and established in 2013, Atlantic International Corp. (which operated as SeqLL Inc. until its name change in June 2024) underwent a significant corporate change on June 18, 2024, when it was acquired by Lyneer Investments, LLC, via a reverse merger. The company operates within the life sciences sector, providing specialized instrumentation and research services.
Analysis Summary
Atlantic International Corp. reported revenue of $435.9M in the most recent fiscal year, growing at a 5-year CAGR of 321.0%.
Trailing-twelve-month margins: gross margin 8.6%, operating margin -7.8%, net margin -19.4%.
At the current price of $0.90, ATLN has negative trailing earnings (P/E not meaningful) and an ROE of -83.20%. Market capitalisation stands at $73M.
Balance sheet quality for ATLN: current ratio of 0.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 7.10 |
| EV / EBITDA | -3.31 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ATLN | Atlantic International Corp. | $73M | 7.10 | -83.2% | |
| RPRX | Royalty Pharma plc | $26.0B | 24.39 | 3.83 | |
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $11.7B | 217.89 | 16.92 | 8.4% |
| LQDA | Liquidia Corporation | $5.8B | 43.62 | 31.18 | 149.6% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.8B | 70.23 | 8.91 | 13.7% |
| 0HF9.L | Amicus Therapeutics, Inc. | $5.3B | |||
| PBH | Prestige Consumer Healthcare Inc. | $2.2B | 13.05 | 1.16 |
Price
| Price | $0.90 |
| Market Cap | $73M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -8319.60% |
| Return on Invested Capital | -16.39% |
| Return on Assets | -16.06% |
| Gross Margin | 8.58% |
| Operating Margin | -7.80% |
| Net Margin | -19.39% |
Related companies: ASH.AX · CHZ.SI · CIRC · CWLPF · HQI · ILLR · IPDN
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of ATLN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks